Clinical Trial Detail

NCT ID NCT02996474
Title Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Heart, Lung, and Blood Institute (NHLBI)
Indications

acute myeloid leukemia

Therapies

Decitabine + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.